Esperion Therapeutics Inc (ESPR) saw its loss widen to $40.54 million, or $1.80 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $14.58 million, or $0.65 a share. The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $40.89 million, compared with an operating loss of $14.82 million in the previous year period.
“With FDA having confirmed the pathway to approval for an LDL-C lowering indication for bempedoic acid, we remain on track to submit the NDA and MAA global regulatory filings by the first half of 2019. We expect to begin reporting top-line results from our global pivotal Phase 3 studies starting in the second quarter of 2018,” said Tim Mayleben, president and chief executive officer of Esperion Therapeutics. “Our near-term focus is the completion of patient enrollment in our Phase 3 LDL-C lowering efficacy studies, and later this quarter we look forward to announcing details of our clinical development and regulatory strategy for our doublet pill, the fixed dose combination of bempedoic acid and ezetimibe.”
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
